Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Basal Cell 6Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 3Cholangiocarcinoma 3Tongue Neoplasms 2Pleural Diseases 2Mycosis Fungoides 2Mesothelioma, Malignant 2Keratosis, Actinic 2Bile Duct Neoplasms 2Basal Cell Nevus Syndrome 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomatitis 1Skin Neoplasms 1Sezary Syndrome 1Salivary Gland Neoplasms 1Photosensitivity Disorders 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Epitheliod Malignant Pleural Mesothelioma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 7Paclitaxel 4Cisplatin 3Carboplatin 3camrelizumab 2Radiotherapy 2Radiosurgery 2Nivolumab 2Immunotherapy 2Immune Checkpoint Inhibitors 2tremelimumab 1toripalimab 1spartalizumab 1sinoporphyrin sodium 1poly ICLC 1penpulimab 1durvalumab 1avelumab 1Tramadol 1Tadalafil 1Surgical Procedures, Operative 1S 1 (combination) 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Photochemotherapy 1Pemetrexed 1Oxaliplatin 1Morphine 1Leucovorin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Parkinson Disease 4, Autosomal Dominant Lewy Body × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Unknown
54 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡